Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and the best dose of sunitinib malate when given
together with bevacizumab in treating patients with kidney cancer or advanced solid
malignancies. Sunitinib malate may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth or by blocking blood flow to the tumor. Monoclonal antibodies,
such as bevacizumab, can block tumor growth in different ways. Some block the ability of
tumor to grow and spread. Others find tumor cells and help kill them or carry cancer-killing
substances to them. Giving sunitinib malate together with bevacizumab may kill more tumor
cells.